Davidson Capital Management Inc. Buys 2,272 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Davidson Capital Management Inc. raised its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 34.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,926 shares of the medical instruments supplier’s stock after purchasing an additional 2,272 shares during the period. Davidson Capital Management Inc.’s holdings in West Pharmaceutical Services were worth $2,940,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of WST. Fidelis Capital Partners LLC purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at approximately $27,000. Crewe Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 71 shares during the period. Quarry LP grew its position in shares of West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. bought a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in West Pharmaceutical Services during the 1st quarter worth about $40,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Up 0.6 %

Shares of WST opened at $310.92 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The stock has a market cap of $22.65 billion, a PE ratio of 41.02, a P/E/G ratio of 10.58 and a beta of 1.01. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $304.11 and its 200-day moving average price is $337.96.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. During the same period last year, the company posted $2.11 EPS. The business’s revenue was down 6.9% on a year-over-year basis. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.53% of the stock is owned by corporate insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.